Replies to post #248566 on Biotech Values

[jbog]

rwwine,

After doing a couple of back of the napkins notes this is what I come up with over the last 6 quarters:

RHA SALES (mil)
$20.8
$25.4
$26.1
$34.7
$30.2
$31.7

Daxi (only 3 periods but not complete):
$10.9
$15.3
$22.6

Expenses:
$87.4
$86.2
$106
$125 (less $69m writeoff)
$107.3
$123.6

I kinda remember that some new RHA fillers are coming out but as of now it looks like RHA is close to it's saturation point which makes no sense considering how big the market is.

As Daxi came on the market it looks like their expenses have increase rather significantly. I'm sure sales will continue to increase over time but I certainly thought they'd be better than 5% of Botox's size with all the hoopla surrounding the rollout.

I never thought it would be hard to attract customers compared to keeping customers.

They might need to adjust product pricing because it looks like the injectors have increased their charges to compensate for the reduced visits.